Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg / Amlodipine 10 mg in Patients With Essential Hypertension

NCT00402103 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00402103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00402103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg / Amlodipine 10 mg in Patients With Essential Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
April 30, 2008
Enrollment
556 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension